Sartorius AG (Sartorius AG) Debt-to-EBITDA : 5.53 (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sartorius AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sartorius AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $366 Mil. Sartorius AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5,286 Mil. Sartorius AG's annualized EBITDA for the quarter that ended in Mar. 2024 was $1,023 Mil. Sartorius AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 5.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sartorius AG's Debt-to-EBITDA or its related term are showing as below:

SARTF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.65 Med: 2.37 Max: 6.08
Current: 6.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sartorius AG was 6.08. The lowest was 1.65. And the median was 2.37.

SARTF's Debt-to-EBITDA is ranked worse than
89.04% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs SARTF: 6.06

Sartorius AG Debt-to-EBITDA Historical Data

The historical data trend for Sartorius AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Debt-to-EBITDA Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

2.37

3.33

2.24

1.69

6.08

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															2.39	2.43	7.39	8.54	5.53

Competitive Comparison of Sartorius AG's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Sartorius AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sartorius AG's Debt-to-EBITDA falls into.

Sartorius AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sartorius AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(314.068	+	5477.972)	/	952.126
	=	6.08

Sartorius AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(365.761	+	5285.87)	/	1022.608
	=	5.53

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Sartorius AG (OTCPK:SARTF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sartorius AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (Sartorius AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.